| ［1］ |
Brauner A， Fridman O， Gefen O， et al. Distinguishing between resistance， tolerance and persistence to antibiotic treatment［J］. Nat Rev Microbiol， 2016， 14（5）： 320-330.
|
| ［2］ |
Waldvogel FA， Medoff G， Swartz MN. Osteomyelitis： a review of clinical features， therapeutic considerations and unusual aspects［J］. N Engl J Med， 1970， 282（4）： 198-206.
|
| ［3］ |
Dauchy FA， Dutronc H，Cazanave C，et al. Infectious diseases society of america guidelines for the diagnosis and management of prosthetic joint infection： what is the correct duration of antibiotic treatment？［J］. Clin Infect Dis， 2013， 57（1）： 160-161.
|
| ［4］ |
Zimmerli W， Trampuz A， Ochsner PE. Prosthetic-joint infections［J］. N Engl J Med， 2004， 351（16）： 1645-1654.
|
| ［5］ |
Osmon DR， Berbari EF， Berendt AR， et al. Diagnosis and management of prosthetic joint infection： clinical practice guidelines by the infectious diseases society of America［J］. Clin Infect Dis， 2013， 56（1）： e1-e25.
|
| ［6］ |
Valour F， Karsenty J， Bouaziz A， et al. Antimicrobial-related severe adverse events during treatment of bone and joint infection due to Methicillin-susceptible Staphylococcus aureus［J］. Antimicrob Agents Chemother，2014， 58（2）： 746-755.
|
| ［7］ |
Schindler M，Bernard L，Belaieff W，et al. Epidemiology of adverse events and Clostridium difficile-associated diarrhea during long-term antibiotic therapy for osteoarticular infections［J］. J Infect， 2013， 67（5）： 433-438.
|
| ［8］ |
MacDougall C， Powell JP， Johnson CK， et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals［J］. Clin Infect Dis， 2005， 41（4）： 435-440.
|
| ［9］ |
Argenson JN， Arndt M， Babis G， et al. Hip and knee section， treatment， debridement and retention of implant： proceedings of international consensus on orthopedic infections［J］. J Arthroplasty， 2019， 34（2）： S399-S419.
|
| ［10］ |
Jia Y，Chen J， Liang W， et al. Differences in efficacy between short- and long-course antibiotic agents for joint prosthesis infection： a systematic review and meta-analysis［J］. Surg Infect（Larchmt），2022， 23（7）： 616-624.
|
| ［11］ |
Olearo F， Zanichelli V， Exarchakou A， et al. The impact of antimicrobial therapy duration in the treatment of prosthetic joint infections depending on surgical strategies： a systematic review and meta-analysis［J］. Open Forum Infect Dis， 2023， 10（5）：ofad246.
|
| ［12］ |
Chen Y， Ding H， Wang Q， et al. Can "LITE" procedure combined with a short course antibiotic treatment be effective in treating the chronic PJI？-A prospective randomized controlled trial［J］. Orthop Surg， 2025， 17（1）： 94-104.
|
| ［13］ |
Bernard L， Arvieux C， Brunschweiler B， et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection［J］. N Engl J Med， 2021， 384（21）： 1991-2001.
|
| ［14］ |
Atkins D， Best D， Briss PA， et al. Grading quality of evidence and strength of recommendations［J］. BMJ， 2004， 328（7454）： 1490.
|
| ［15］ |
Westberg M， Grøgaard B， Snorrason F. Early prosthetic joint infections treated with debridement and implant retention： 38 primary hip arthroplasties prospectively recorded and followed for median 4 years［J］. Acta Orthop， 2012， 83（3）： 227-232.
|
| ［16］ |
Kuiper JW， Vos SJ， Saouti R， et al. Prosthetic joint-associated infections treated with DAIR （debridement， antibiotics， irrigation， and retention）： analysis of risk factors and local antibiotic carriers in 91 patients［J］. Acta Orthop， 2013， 84（4）： 380-386.
|
| ［17］ |
Bernard L， Legout L， Zürcher-Pfund L， et al. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty［J］. J Infect， 2010， 61（2）： 125-132.
|
| ［18］ |
Puhto AP， Puhto T， Syrjala H. Short-course antibiotics for prosthetic joint infections treated with prosthesis retention［J］. Clin Microbiol Infect， 2012， 18（11）： 1143-1148.
|
| ［19］ |
Chaussade H， Uçkay I， Vuagnat A， et al. Antibiotic therapy duration for prosthetic joint infections treated by debridement and implant retention （DAIR）： similar long-term remission for 6 weeks as compared to 12 weeks［J］. Int J Infect Dis， 2017， 63： 37-42.
|
| ［20］ |
Gehrke T， Zahar A， Kendoff D. One-stage exchange： it all began here［J］. Bone Joint J， 2013， 95-B（11 Suppl A）： 77-83.
|
| ［21］ |
Klatte TO，Kendoff D，Kamath AF， et al. Single-stage revision for fungal peri-prosthetic joint infection： a single-centre experience［J］. Bone Joint J， 2014， 96-B（4）： 492-496.
|
| ［22］ |
Razii N， Clutton JM， Kakar R， et al. Single-stage revision for the infected total knee arthroplasty ： the Cardiff experience［J］. Bone Jt Open， 2021， 2（5）： 305-313.
|
| ［23］ |
Klemt C， Tirumala V， Oganesyan R， et al. Single-stage revision of the infected total knee arthroplasty is associated with improved functional outcomes： a propensity score-matched cohort study［J］. J Arthroplasty， 2021， 36（1）： 298-304.
|
| ［24］ |
Tuecking LR， Silligmann J， Savov P， et al. Detailed revision risk analysis after single- vs. two-stage revision total knee arthroplasty in periprosthetic joint infection： a retrospective tertiary center analysis［J］. Antibiotics （Basel）， 2021， 10（10）：1177.
|
| ［25］ |
Hart WJ， Jones RS. Two-stage revision of infected total knee replacements using articulating cement spacers and short-term antibiotic therapy［J］. J Bone Joint Surg Br， 2006， 88（8）： 1011-1015.
|
| ［26］ |
Mittal Y， Fehring TK， Hanssen A， et al. Two-stage reimplantation for periprosthetic knee infection involving resistant organisms［J］. J Bone Joint Surg Am， 2007， 89（6）： 1227-1231.
|
| ［27］ |
Whittaker JP， Warren RE， Jones RS，et al. Is prolonged systemic antibiotic treatment essential in two-stage revision hip replacement for chronic gram-positive infection？［J］. J Bone Joint Surg Br， 2009， 91（1）： 44-51.
|
| ［28］ |
Bejon P， Berendt A， Atkins BL， et al. Two-stage revision for prosthetic joint infection： predictors of outcome and the role of reimplantation microbiology［J］. J Antimicrob Chemother， 2010， 65（3）： 569-575.
|
| ［29］ |
Ascione T， Balato G， Mariconda M， et al. Continuous antibiotic therapy can reduce recurrence of prosthetic joint infection in patients undergoing 2-stage exchange［J］. J Arthroplasty， 2019， 34（4）： 704-709.
|
| ［30］ |
Tan TL， Kheir MM， Rondon AJ， et al. Determining the role and duration of the "antibiotic holiday" period in periprosthetic joint infection［J］. J Arthroplasty， 2018， 33（9）： 2976-2980.
|
| ［31］ |
Barbero Allende JM， Fernández Antón E， Gómez-Junyent J， et al. Impact of antibiotic prophylaxis in second-stage surgery in joint prosthesis infection treated with two-stage exchange. A multicenter case-control study［J］. Eur J Clin Microbiol Infect Dis， 2024， 43（7）： 1319-1328.
|
| ［32］ |
Zmistowski B， Tetreault MW， Alijanipour P， et al. Recurrent periprosthetic joint infection： persistent or new infection？［J］. J Arthroplasty， 2013， 28（9）： 1486-1489.
|
| ［33］ |
Frank JM， Kayupov E， Moric M， et al. The Mark Coventry， MD， award： oral antibiotics reduce reinfection after two-stage exchange： a multicenter， randomized controlled trial［J］. Clin Orthop Relat Res， 2017， 475（1）： 56-61.
|
| ［34］ |
Saade A，Urvoy JM，Luque Paz D，et al. Microbiology and antibiotics after second-stage revision of periprosthetic joint infections： a two-year follow-up cohort［J］. Infect Dis Now， 2022， 52（6）： 358-364.
|
| ［35］ |
Zywiel MG，Johnson AJ，Stroh DA，et al. Prophylactic oral antibiotics reduce reinfection rates following two-stage revision total knee arthroplasty［J］. Int Orthop， 2011， 35（1）： 37-42.
|
| ［36］ |
Fang X， Wang Q， Yang X， et al. What is the appropriate extended duration of antibiotic prophylaxis after two-stage revision for chronic PJI？［J］. Bone Joint Res， 2021， 10（12）： 790-796.
|
| ［37］ |
杨青君，曹力. 人工关节假体周围感染的抗生素应用［J］. 临床医学进展，2023， 13（5）： 8300-8305.
|
| ［38］ |
Senneville E， Joulie D， Legout L， et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus［J］. Clin Infect Dis， 2011， 53（4）： 334-340.
|
| ［39］ |
Berdal JE，Skråmm I，Mowinckel P，et al. Use of Rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections［J］. Clin Microbiol Infect， 2005， 11（10）： 843-845.
|
| ［40］ |
Lee HD， Prashant K， Shon WY. Management of periprosthetic hip joint infection［J］. Hip Pelvis， 2015， 27（2）： 63-71.
|
| ［41］ |
Navarro G， Lozano L， Sastre S， et al. Experiences during switching from two-stage to one-stage revision arthroplasty for chronic total knee arthroplasty infection［J］. Antibiotics （Basel）， 2021， 10（12）：1436.
|
| ［42］ |
Wang HY， Zhang Md R， Luo ZY， et al. One-stage arthroplasty or revision for seronegative infections in hip and knee［J］. Orthop Surg， 2020， 12（1）： 38-49.
|
| ［43］ |
Singer J， Merz A， Frommelt L， Fink B. High rate of infection control with one-stage revision of septic knee prostheses excluding MRSA and MRSE［J］. Clin Orthop Relat Res， 2012， 470（5）： 1461-1471.
|
| ［44］ |
Siddiqi A， Nace J， George NE， et al. Primary total knee arthroplasty implants as functional prosthetic spacers for definitive management of periprosthetic joint infection： a multicenter study［J］. J Arthroplasty， 2019， 34（12）： 3040-3047.
|
| ［45］ |
Osmon DR，Berbari EF，Berendt AR， et al. Executive summary： diagnosis and management of prosthetic joint infection： clinical practice guidelines by the infectious diseases society of America［J］. Clin Infect Dis， 2013， 56（1）： 1-10.
|
| ［46］ |
Tice AD， Rehm SJ， Dalovisio JR， et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines［J］. Clin Infect Dis， 2004， 38（12）： 1651-1672.
|
| ［47］ |
Scarborough M， Li HK， Rombach I， et al. Oral versus intravenous antibiotics for bone and joint infections： the OVIVA non-inferiority RCT［J］. Health Technol Assess， 2019， 23（38）： 1-92.
|
| ［48］ |
Bouji N， Wen S， Dietz MJ. Intravenous antibiotic duration in the treatment of prosthetic joint infection： systematic review and meta-analysis［J］. J Bone Jt Infect， 2022， 7（5）： 191-202.
|
| ［49］ |
Boclé H， Lavigne JP， Cellier N， et al. Effectiveness of early switching from intravenous to oral antibiotic therapy in Staphylococcus aureus prosthetic bone and joint or orthopedic metalware-associated infections［J］. BMC Musculoskelet Disord， 2021， 22（1）： 315.
|
| ［50］ |
Hsieh PH， Huang KC， Lee PC，et al. Two-stage revision of infected hip arthroplasty using an antibiotic-loaded spacer： retrospective comparison between short-term and prolonged antibiotic therapy［J］. J Antimicrob Chemother， 2009， 64（2）： 392-397.
|
| ［51］ |
McKenna PB， O'Shea K， Masterson EL. Two-stage revision of infected hip arthroplasty using a shortened post-operative course of antibiotics［J］. Arch Orthop Trauma Surg， 2009， 129（4）： 489-494.
|
| ［52］ |
Oussedik SI， Dodd MB， Haddad FS. Outcomes of revision total hip replacement for infection after grading according to a standard protocol［J］. J Bone Joint Surg Br， 2010， 92（9）： 1222-1226.
|
| ［53］ |
Duquette E， Bhatti P， Sur S， et al. History and use of antibiotic irrigation for preventing surgical site infection in neurosurgery： a scoping review［J］. World Neurosurg， 2022， 160： 76-83.
|
| ［54］ |
Duan MY， Zhang HZ. Vancomycin lavage for the incidence of acute surgical site infection following primary total hip arthroplasty and total knee arthroplasty［J］. World J Clin Cases， 2022， 10（1）： 71-78.
|
| ［55］ |
Wu X， Chen W， Rong R， et al. Application of the new irrigation protocol to reduce recurrence rate in the management of periprosthetic joint infection［J］. Orthop Surg， 2024， 16（3）： 577-584.
|
| ［56］ |
Siddiqi A， Abdo ZE， Rossman SR， et al. What is the optimal irrigation solution in the management of periprosthetic hip and knee joint infections？［J］. J Arthroplasty， 2021， 36（10）： 3570-3583.
|
| ［57］ |
Marquez-Gomez M， Diaz-Navarro M， Visedo A， et al. An in vitro study to assess the best strategy for the chemical debridement of periprosthetic joint infection［J］. Antibiotics （Basel）， 2023， 12（10）：1507.
|
| ［58］ |
Azzam KA， Seeley M， Ghanem E， et al. Irrigation and debridement in the management of prosthetic joint infection： traditional indications revisited［J］. J Arthroplasty， 2010， 25（7）： 1022-1027.
|
| ［59］ |
Koyonos L， Zmistowski B， Della Valle CJ， et al. Infection control rate of irrigation and débridement for periprosthetic joint infection［J］. Clin Orthop Relat Res， 2011， 469（11）： 3043-3048.
|
| ［60］ |
Tsumura H， Ikeda S， Ono T， et al. Synovectomy， debridement， and continuous irrigation for infected total knee arthroplasty［J］. Int Orthop， 2005， 29（2）： 113-116.
|
| ［61］ |
Fukagawa S， Matsuda S， Miura H， et al. High-dose antibiotic infusion for infected knee prosthesis without implant removal［J］. J Orthop Sci， 2010， 15（4）： 470-476.
|
| ［62］ |
Bryan AJ， Abdel MP， Sanders TL， et al. Irrigation and debridement with component retention for acute infection after hip arthroplasty： improved results with contemporary management［J］. J Bone Joint Surg Am， 2017， 99（23）： 2011-2018.
|
| ［63］ |
Tornero E， Morata L， Martínez-Pastor JC， et al. Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention［J］. J Antimicrob Chemother， 2016， 71（5）： 1395-1401.
|
| ［64］ |
Steadman W， Chapman PR， Schuetz M， et al. Local antibiotic delivery options in prosthetic joint infection［J］. Antibiotics （Basel）， 2023， 12（4）：752.
|
| ［65］ |
Ji B，Li G，Zhang X，et al. Effective treatment of single-stage revision using intra-articular antibiotic infusion for culture-negative prosthetic joint infection［J］. Bone Joint J， 2020， 102-B（3）： 336-344.
|
| ［66］ |
Tsukayama DT， Estrada R， Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections［J］. J Bone Joint Surg Am， 1996， 78（4）： 512-523.
|
| ［67］ |
Geurts JA， Janssen DM， Kessels AG， et al. Good results in postoperative and hematogenous deep infections of 89 stable total hip and knee replacements with retention of prosthesis and local antibiotics［J］. Acta Orthop， 2013， 84（6）： 509-516.
|
| ［68］ |
McNally MA， Ferguson JY， Scarborough M， et al. Mid- to long-term results of single-stage surgery for patients with chronic osteomyelitis using a bioabsorbable gentamicin-loaded ceramic carrier［J］. Bone Joint J， 2022， 104-B（9）： 1095-1100.
|
| ［69］ |
Saginur R， Stdenis M， Ferris W， et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections［J］. Antimicrob Agents Chemother，2006， 50（1）： 55-61.
|
| ［70］ |
Major Extremity Trauma Research Consortium （METRC）， O'Toole RV， Joshi M， et al. Effect of intrawound vancomycin powder in operatively treated high-risk tibia fractures： a randomized clinical trial［J］. JAMA Surg， 2021， 156（5）： e207259.
|
| ［71］ |
Edelstein AI，Weiner JA，Cook RW，et al. Intra-articular Vancomycin powder eliminates Methicillin-resistant S. aureus in a rat model of a contaminated intra-articular implant［J］. J Bone Joint Surg Am， 2017， 99（3）： 232-238.
|
| ［72］ |
Johnson JD， Nessler JM， Horazdovsky RD， et al. Serum and wound vancomycin levels after intrawound administration in primary total joint arthroplasty［J］. J Arthroplasty， 2017， 32（3）： 924-928.
|
| ［73］ |
Roy ME，Peppers MP，Whiteside LA，et al. Vancomycin concentration in synovial fluid： direct injection into the knee vs. intravenous infusion［J］. J Arthroplasty， 2014， 29（3）： 564-568.
|
| ［74］ |
Riesgo AM， Park BK， Herrero CP， et al. Vancomycin povidone-iodine protocol improves survivorship of periprosthetic joint infection treated with irrigation and debridement［J］. J Arthroplasty， 2018， 33（3）： 847-850.
|
| ［75］ |
Wei J， Wen Y， Tong K， et al. Local application of Vancomycin in one-stage revision of prosthetic joint infection caused by Methicillin-resistant Staphylococcus aureus［J］. Antimicrob Agents Chemother， 2021， 65（9）： e0030321.
|
| ［76］ |
Mu W， Xu B， Guo W， et al. Outcome of irrigation and debridement with topical antibiotics delivery for the management of periprosthetic joint infection occurring within 3 months since the primary total joint arthroplasty［J］. J Arthroplasty， 2021， 36（5）： 1765-1771.
|
| ［77］ |
董国华，刘玉龙，梁明，等. 局部高药物浓度抗生素治疗固定平台单髁置换术后MRSA感染1例并文献复习［J］. 实用骨科杂志，2024， 30（3）： 277-280.
|
| ［78］ |
Whiteside LA， Peppers M， Nayfeh TA，et al. Methicillin-resistant Staphylococcus aureus in TKA treated with revision and direct intra-articular antibiotic infusion［J］. Clin Orthop Relat Res， 2011， 469（1）： 26-33.
|
| ［79］ |
Zheng Z， Stewart PS. Penetration of Rifampin through Staphylococcus epidermidis biofilms［J］. Antimicrob Agents Chemother， 2002， 46（3）： 900-903.
|
| ［80］ |
Zimmerli W， Sendi P. Role of Rifampin against staphylococcal biofilm infections in vitro， in animal models， and in orthopedic-device-related infections［J］. Antimicrob Agents Chemother， 2019， 63（2）：e01746-18.
|
| ［81］ |
Becker A， Kreitmann L， Triffaut-Fillit C， et al. Duration of Rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement， antibiotics and implant retention （DAIR）： a retrospective multicenter study in France［J］. J Bone Jt Infect， 2020， 5（1）： 28-34.
|
| ［82］ |
El Helou OC， Berbari EF， Lahr BD， et al. Efficacy and safety of Rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention［J］. Eur J Clin Microbiol Infect Dis， 2010， 29（8）： 961-967.
|
| ［83］ |
Beldman M， Löwik C， Soriano A， et al. If， when， and how to use Rifampin in acute staphylococcal periprosthetic joint infections， a multicentre observational study［J］. Clin Infect Dis， 2021， 73（9）： 1634-1641.
|
| ［84］ |
Zimmerli W， Widmer AF， Blatter M， et al. Role of Rifampin for treatment of orthopedic implant–related staphylococcal infections a randomized controlled trial［J］. JAMA， 1998， 279（19）： 1537-1541.
|
| ［85］ |
Pushkin R， Iglesias-Ussel MD， Keedy K， et al. A randomized study evaluating oral fusidic acid （CEM-102） in combination with oral Rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections： a newly identified drug–drug interaction［J］. Clin Infect Dis， 2016， 63（12）： 1599-1604.
|
| ［86］ |
Karlsen ØE，Borgen P，Bragnes B，et al. Rifampin combination therapy in Staphylococcal prosthetic joint infections： a randomized controlled trial［J］. J Orthop Surg Res， 2020， 15（1）：365.
|
| ［87］ |
Aboltins CA， Page MA， Buising KL， et al. Treatment of staphylococcal prosthetic joint infections with debridement， prosthesis retention and oral Rifampicin and fusidic acid［J］. Clin Microbiol Infect， 2007， 13（6）： 586-591.
|
| ［88］ |
Soriano A， García S， Bori G， et al. Treatment of acute post-Surgical infection of joint arthroplasty［J］. Clin Microbiol Infect， 2006， 12（9）： 930-933.
|
| ［89］ |
Drancourt M， Stein A， Argenson JN， et al. Oral treatment of staphylococcus spp. infected orthopaedic implants with fusidic acid or Ofloxacin in combination with Rifampicin［J］. J Antimicrob Chemother， 1997， 39（2）： 235-240.
|
| ［90］ |
Tonnelier M， Bouras A， Joseph C， et al. Impact of Rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp： a retrospective single-center study in France［J］. BMC Infect Dis， 2021， 21（1）：174.
|
| ［91］ |
Nguyen S， Robineau O， Titecat M， et al. Influence of daily dosage and frequency of administration of Rifampicin–Levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections［J］. Eur J Clin Microbiol Infect Dis， 2015， 34（8）： 1675-1682.
|
| ［92］ |
Colmenero JD， Fernández-Gallardo LC， Agúndez JA， et al. Possible implications of Doxycycline-Rifampin interaction for treatment of brucellosis［J］. Antimicrob Agents Chemother， 1994， 38（12）： 2798-2802.
|
| ［93］ |
Okazaki F，Tsuji Y，Seto Y， et al. Effects of a Rifampicin pre-treatment on linezolid pharmacokinetics［J］. PLoS One， 2019， 14（9）： e0214037.
|
| ［94］ |
Ribera E， Pou L， Fernandez-Sola A， et al. Rifampin reduces concentrations of Trimethoprim and Sulfamethoxazole in serum in human immunodeficiency virus-infected patients［J］. Antimicrob Agents Chemother， 2001， 45（11）： 3238-3241.
|
| ［95］ |
Goulenok T， Seurat J， Selle A， et al. Pharmacokinetic interaction between Rifampicin and Clindamycin in staphylococcal osteoarticular infections［J］. Int J Antimicrob Agents， 2023， 62（2）： 106885.
|
| ［96］ |
Thompson JM， Saini V， Ashbaugh AG， et al. Oral-only linezolid-Rifampin is highly effective compared with other antibiotics for periprosthetic joint infection： study of a mouse model［J］. J Bone J Surg， 2017， 99（8）： 656-665.
|
| ［97］ |
Porrino J， Wang A， Moats A， et al. Prosthetic joint infections： diagnosis， management， and complications of the two-stage replacement arthroplasty［J］. Skeletal Radiol， 2020， 49（6）： 847-859.
|
| ［98］ |
Randelli P， Evola FR， Cabitza P， et al. Prophylactic use of antibiotic-loaded bone cement in primary total knee replacement［J］. Knee Surg Sports Traumatol Arthrosc， 2010， 18（2）： 181-186.
|
| ［99］ |
Sukeik M， Haddad FS. Two-stage procedure in the treatment of late chronic hip infections-spacer implantation［J］. Int J Med Sci， 2009， 6（5）： 253-257.
|
| ［100］ |
Kini SG， Gabr A， Das R， et al. Two-stage revision for periprosthetic hip and knee joint infections［J］. Open Orthop J， 2016， 10： 579-588.
|
| ［101］ |
Samelis PV， Papagrigorakis E， Sameli E， et al. Current concepts on the application， pharmacokinetics and complications of antibiotic-loaded cement spacers in the treatment of prosthetic joint infections［J］. Cureus， 2022， 14（1）： e20968.
|
| ［102］ |
Naoum S， Koutserimpas C， Pantekidis I， et al. Antimicrobial regimens in cement spacers for periprosthetic joint infections： a critical review［J］. Antibiotics （Basel）， 2024， 13（8）： 722.
|
| ［103］ |
Corona PS， Espinal L， Rodríguez-Pardo D， et al. Antibiotic susceptibility in gram-positive chronic joint arthroplasty infections： increased aminoglycoside resistance rate in patients with prior aminoglycoside-impregnated cement spacer use［J］. J Arthroplasty， 2014， 29（8）： 1617-1621.
|
| ［104］ |
Kuzyk PR， Dhotar HS， Sternheim A， et al. Two-stage revision arthroplasty for management of chronic periprosthetic hip and knee infection： techniques， controversies， and outcomes［J］. J Am Acad Orthop Surg， 2014， 22（3）： 153-164.
|
| ［105］ |
Parvizi J， Azzam K， Ghanem E， et al. Periprosthetic infection due to resistant Staphylococci： serious problems on the horizon［J］. Clin Orthop Relat Res， 2009， 467（7）： 1732-1739.
|
| ［106］ |
Wei J， Zhou S， Gu H， et al. Meropenem-loaded cement is effective in preventing gram-negative osteomyelitis in an animal model［J］. Clin Orthop Relat Res， 2023， 481（1）： 177-189.
|
| ［107］ |
Penner MJ， Duncan CP， Masri BA. The in vitro elution characteristics of antibiotic-loaded CMW and Palacos-R bone cements［J］. J Arthroplasty， 1999， 14（2）： 209-214.
|
| ［108］ |
Bingham J. When and how should I use antibiotic cement in primary and revision joint arthroplasty？［J］. J Arthroplasty， 2022， 37（8）： 1435-1437.
|
| ［109］ |
Wahlig H， Dingeldein E， Buchholz HW， et al. Pharmacokinetic study of Gentamicin-loaded cement in total hip replacements. Comparative effects of varying dosage［J］. J Bone Joint Surg Br， 1984， 66（2）： 175-179.
|
| ［110］ |
Triantafyllopoulos GK， Memtsoudis SG， Zhang W， et al. Periprosthetic infection recurrence after 2-stage exchange arthroplasty： failure or fate？［J］. J Arthroplasty， 2017， 32（2）： 526-531.
|
| ［111］ |
Akgün D， Müller M， Perka C， et al. A positive bacterial culture during re-implantation is associated with a poor outcome in two-stage exchange arthroplasty for deep infection［J］. Bone Joint J， 2017， 99-B（11）： 1490-1495.
|
| ［112］ |
Suardi V， Logoluso N， Anghilieri FM， et al. Reimplantation after periprosthetic joint infection： the role of microbiology［J］. Antibiotics （Basel）， 2022， 11（10）： 1408.
|
| ［113］ |
Theil C， Freudenberg SC， Gosheger G， et al. Do positive cultures at second stage re-implantation increase the risk for reinfection in two-stage exchange for periprosthetic joint infection？［J］. J Arthroplasty， 2020， 35（10）： 2996-3001.
|
| ［114］ |
Puhto AP， Puhto TM， Niinimäki TT， et al. Two-stage revision for prosthetic joint infection： outcome and role of reimplantation microbiology in 107 cases［J］. J Arthroplasty， 2014， 29（6）： 1101-1104.
|
| ［115］ |
Xu C， Tan TL， Chen JY. Positive culture during reimplantation increases the risk of reinfection in two-stage exchange arthroplasty despite administrating prolonged antibiotics： a retrospective cohort study and meta-analysis［J］. J Arthroplasty， 2019， 34（5）： 1025-1031.
|
| ［116］ |
Parvizi J， Tan TL， Goswami K， et al. The 2018 definition of periprosthetic hip and knee infection： an evidence-based and validated criteria［J］. J Arthroplasty， 2018， 33（5）： 1309-1314. e2.
|
| ［117］ |
Tarabichi M， Shohat N， Goswami K， et al. Diagnosis of periprosthetic joint infection： the potential of next-generation sequencing［J］. J Bone Joint Surg Am， 2018， 100（2）： 147-154.
|
| ［118］ |
Goswami K， Clarkson S， Phillips CD， et al. An enhanced understanding of culture-negative periprosthetic joint infection with next-generation sequencing： a multicenter study［J］. J Bone Joint Surg Am， 2022， 104（17）： 1523-1529.
|
| ［119］ |
Zappe B， Graf S， Ochsner PE， et al. Propionibacterium spp. in prosthetic joint infections： a diagnostic challenge［J］. Arch Orthop Trauma Surg， 2008， 128（10）： 1039-1046.
|
| ［120］ |
Fida M， Tande AJ. State-of-the-art metagenomic sequencing and its role in the diagnosis of periprosthetic joint infections［J］. Infect Dis Clin North Am， 2024， 38（4）： 813-825.
|
| ［121］ |
Tan J， Liu Y， Ehnert S， et al. The effectiveness of metagenomic next-generation sequencing in the diagnosis of prosthetic joint infection： a systematic review and meta-analysis［J］. Front Cell Infect Microbiol， 2022， 12： 875822.
|
| ［122］ |
Hao L， Bian W， Qing Z， et al. Will previous antimicrobial therapy reduce the positivity rate of metagenomic next-generation sequencing in periprosthetic joint infections？A clinical study［J］. Front Cell Infect Microbiol， 2024， 13： 1295962.
|
| ［123］ |
Ding H， Huang J， Lin L， et al. Shedding light on negative cultures in osteoarticular infections： leveraging mNGS to unravel risk factors and microbial profiles［J］. Front Cell Infect Microbiol， 2024， 14： 1457639.
|
| ［124］ |
Tarabichi M， Shohat N， Goswami K， et al. Can next generation sequencing play a role in detecting pathogens in synovial fluid?［J］. Bone Joint J， 2018， 100-B（2）： 127-133.
|
| ［125］ |
Thoendel MJ， Jeraldo PR， Greenwood-Quaintance KE， et al. Identification of prosthetic joint infection pathogens using a shotgun metagenomics approach［J］. Clin Infect Dis， 2018， 67（9）： 1333-1338.
|
| ［126］ |
Ivy MI， Thoendel MJ， Jeraldo PR， et al. Direct detection and identification of prosthetic joint infection pathogens in synovial fluid by metagenomic shotgun sequencing［J］. J Clin Microbiol， 2018， 56（9）： e00402-e00418.
|
| ［127］ |
Tan J， Wu L， Zhan L， et al. Optimal selection of specimens for metagenomic next-generation sequencing in diagnosing periprosthetic joint infections［J］. Front Cell Infect Microbiol， 2024， 14： 1356804.
|
| ［128］ |
He R， Wang Q， Wang J， et al. Better choice of the type of specimen used for untargeted metagenomic sequencing in the diagnosis of periprosthetic joint infections［J］. Bone Joint J， 2021， 103-B（5）： 923-930.
|
| ［129］ |
Wang Q， Miao Q， Pan J， et al. The clinical value of metagenomic next-generation sequencing in the microbiological diagnosis of skin and soft tissue infections［J］. Int J Infect Dis， 2020， 100： 414-420.
|
| ［130］ |
Pan TJ， Luo WW， Zhang SS， et al. The clinical application value of multi-site mNGS detection of patients with sepsis in intensive care units［J］. BMC Infect Dis， 2024， 24（1）： 920.
|
| ［131］ |
Hu H， Ding H， Lyu J， et al. Detection of rare microorganisms in bone and joint infections by metagenomic next-generation sequencing［J］. Bone Joint Res， 2024， 13（8）： 401-410.
|
| ［132］ |
Cai Y， Ding H， Chen X， et al. Optimization and standardization of mNGS-based procedures for the diagnosis of mycoplasma periprosthetic joint infection：a novel diagnostic strategy for rare bacterial periprosthetic joint infection［J］. Front Cell Infect Microbiol， 2023， 13： 1089919.
|
| ［133］ |
Goswami K， Clarkson S， Dennis DA， et al. Reinfection or persistence of periprosthetic joint infection？Next generation sequencing reveals new findings［J］. Orthopaedic Proceedings， 2020， 102-B（SUPP_9）： 7.
|
| ［134］ |
Wang C， Huang Z， Li W， et al. Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection？［J］. BMC Infect Dis， 2020， 20（1）： 253.
|
| ［135］ |
Stracy M， Snitser O， Yelin I， et al. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections［J］. Science， 2022， 375（6583）： 889-894.
|
| ［136］ |
Lin C， Li J， Liu B， et al. Metagenomic next-generation sequencing， instead of procalcitonin， could guide antibiotic usage in patients with febrile acute necrotizing pancreatitis： a multicenter， prospective cohort study［J］. Int J Surg， 2024， 110（5）： 2721-2729.
|
| ［137］ |
Siqueira MB， Saleh A， Klika AK， et al. Chronic suppression of periprosthetic joint infections with oral antibiotics increases infection-free survivorship［J］. J Bone Joint Surg Am， 2015， 97（15）： 1220-1232.
|
| ［138］ |
Renz N， Rakow A， Müller M， et al. Long-term antimicrobial suppression prevents treatment failure of streptococcal periprosthetic joint infection［J］. J Infect， 2019， 79（3）： 236-244.
|
| ［139］ |
Zanirato A， Cavagnaro L， Chiarlone F， et al. Periprosthetic joint infection in unicompartmental knee arthroplasty： treatment options and outcomes. What is the current evidence in literature？［J］. Arch Orthop Trauma Surg， 2023， 143（2）： 1031-1039.
|
| ［140］ |
Byren I， Bejon P， Atkins BL， et al. One hundred and twelve infected arthroplasties treated with 'DAIR' （debridement， antibiotics and implant retention）： antibiotic duration and outcome［J］. J Antimicrob Chemother， 2009， 63（6）： 1264-1271.
|
| ［141］ |
Kelly MP， Gililland JM， Blackburn BE， et al. Extended oral antibiotics increase bacterial resistance in patients who fail 2-stage exchange for periprosthetic joint infection［J］. J Arthroplasty， 2022， 37（8S）： S989-S996.
|
| ［142］ |
Mohsen S， Dickinson JA， Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice［J］. Can Fam Physician， 2020， 66（9）： 651-659.
|